Drugs in Dev. Neurology
Phase III
United Kingdom 
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ananda Developments - Ananda Developments Epilepsy Trials
Details : MRX2 (cannabidiol) is a CB1 negative allosteric modulator, small molecule drug candidate, which is indicated for the treatment of refractory early-onset Epilepsy.
Product Name : MRX2
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 21, 2024
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ravulizumab
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Alexion Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Update on CHAMPION-ALS Phase III trial of Ultomiris in Amyotrophic Lateral Sclerosis
Details : The IDMC recommended that the trial be discontinued due to lack of efficacy. No new safety findings were observed and the data were consistent with the established safety profile of Ultomiris.
Product Name : Ultomiris
Product Type : Antibody
Upfront Cash : Inapplicable
August 20, 2021
Lead Product(s) : Ravulizumab
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Alexion Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Cosmo Pharmaceuticals
Deal Size : $143.2 million
Deal Type : Licensing Agreement
Issue of Equity on Share Subscription and Licensing agreement With Cosmo Pharmaceuticals
Details : Acacia Pharma will be responsible for the marketing and distribution of ByFavo in the US in the context of its equity-for-product strategy.
Product Name : Byfavo
Product Type : Other Small Molecule
Upfront Cash : $11.1 million
September 01, 2020
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Cosmo Pharmaceuticals
Deal Size : $143.2 million
Deal Type : Licensing Agreement
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Greenwich Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : U.S. FDA has accepted for filing with Priority Review its recently submitted supplemental New Drug Application for the use of EPIDIOLEX CV to treat seizures in Tuberous Sclerosis Complex.
Product Name : Epidiolex
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 31, 2020
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Greenwich Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
